How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Gastroenterology

Wearable Devices: Weighing the Potential Benefi...

Wearables are electronic devices that are worn on the body part to track, analyze and transmit real-time personal data of the health or workout. The wearables come in different forms and sizes and ...

Jun 30, 2021

Another Failed NASH Drug; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; TLX66 in AL Amyloidosis
TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evaluating the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem...

Find More
recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos
InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...

Find More
recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa
Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company’s lead program developing treatments for C...

Find More

More Views & Analysis

Alpha-1-Antitrypsin-Deficiency-Market-Symptoms-Treatments-Key-Companies
Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market

Alpha1-antitrypsin deficiency (AATD) was first identified by Carl-Bertil Laurell and Sten Eriksson (Laurell and Eriksson 1963) in 1963,  who discovered a link between low plasma serum AAT levels and pulmonary emphysema symptoms. With time as the understanding of the genetic abnormalities grew, AAT deficiency c...

Find More

robot-robotics-in-healthcare-medical-sector-benefits-disadvantages-and-future-scope-applications-uses
How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Artificial intelligence and robotics are the two technologies that have shown the potential to address and provide solutions to many contemporary issues. The manufacturing sector has been using robotics for quite a long time. However, over the past three-four decades, robots are in use in other sectors as well, suc...

Find More

recent-pharma-biotech-news-updates-for-verily-janssen-avrobio
Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

Verily collaborates with Janssen to launch COVID-19 immune response study Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.  The study will be launche...

Find More

recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs

Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo...

Find More

Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Find More

Hepatitis D Market | Hepatitis D Treatment Market | HDV Market
Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook?

Recent years have been experiencing a dramatic increase in the number of Hepatitis D cases. It is spreading at a rapid rate. DelveInsight estimated that the total diagnosed Hepatitis D prevalence was reported to be 204,976 in 2017 in the 7MM (the US, EU5 (the UK, Germany, Spain, France, and Italy) and Japan). Furth...

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More

Major Depressive Disorder (MDD), also known as clinical depression, is a severe, debilitating and fr.....

Find More

In the present scenario, the 3-D printing and bioprinting technology in the medical devices industry.....

Find More

Neuroendocrine tumors (NET) are a rare kind neoplasm that arises from cells of the endocrine (hormon.....

Find More

The pharma industry has played a crucial role in fighting against the pandemic situation by supplyin.....

Find More

In the past few years, online buying has become the easiest way to purchase products and services. T.....

Find More